Proteomics secures licence to oesophageal cancer biomarkers
Filed with ASX · · 2 pages · English
Proteomics International Laboratories Ltd. on 6ix
Story so far
Earlier from Proteomics International Laboratories
- PromarkerD manufacturing tech-transfer completed
- Proteomics awarded $400,000 funding to support manufacturing
- March 2022 Quarterly Activities Report and Appendix 4C
- New Clinical Advisory Board for PromarkerD global rollout
- PromarkerD completes pre-assessment for Medicare rebate
Later from Proteomics International Laboratories
- Endometriosis clinical validation study readout positive
- European PromarkerD patents expanded beyond diabetes
- June 2022 Quarterly Activities Report and Appendix 4C
- Potential breakthrough blood test for endometriosis
- Clinical Utility Study demonstrates PromarkerD test benefits
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories